Furthermore, we showed that rVAR2 resulted in a higher CTC yield in blood samples from prostate, pancreatic, and lung cancer patients as compared to EpCAM-based isolation of patient-matched samples. This evidence concerns the gene EPCAM and lung carcinoma.